- $58.85m
- $69.57m
- $35.59m
- 51
- 28
- 32
- 30
Annual balance sheet for Cytosorbents, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 71.4 | 52.1 | 22.1 | 14.1 | 3.28 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5.16 | 4.52 | 5.66 | 6.06 | 7.32 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 82.5 | 64.3 | 33.8 | 25.4 | 21.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.15 | 18.6 | 23.3 | 22.1 | 20.5 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 90 | 89.5 | 63.2 | 53 | 47.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 10.2 | 13.7 | 9.71 | 14 | 9.82 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 10.7 | 26.9 | 27.9 | 29.5 | 36.3 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 79.2 | 62.6 | 35.4 | 23.5 | 11.1 |
Total Liabilities & Shareholders' Equity | 90 | 89.5 | 63.2 | 53 | 47.4 |
Total Common Shares Outstanding |